Kezar Life Sciences, Inc. (NASDAQ: KZR), a clinical-stage biotechnology company, reported positive top-line results from the Phase 2 clinical trial named MISSION, evaluating zetomipzomib, a novel, first-in-class selective immunoproteasome inhibitor, in patients with active lupus nephritis (LN). The MISSION Phase 2 trial is an open-label study with...
Pandion Therapeutics, Inc. (NASDAQ: PAND), a clinical-stage biotechnology company developing modular biologics for autoimmune regulation, has entered into a definitive agreement with Merck (NYSE: MRK) to be acquired for $60 per share in cash, for an approximate total equity value of $1.85 billion. The acquisition...
Systemic lupus erythematosus (SLE) is an autoimmune disease that causes the body’s immune system to attack healthy tissue causing inflammation, photosensitivity, oral ulcers, pleuritis, joint pain, arthritis, fever and a butterfly rash. In the long-run it can affect the kidneys, brain and heart as well....
